Semaphorin‐3E attenuates intestinal inflammation through the regulation of the communication between splenic CD11C+ and CD4+CD25 T‐cells

Article date: May 2019

By: Laëtitia Kermarrec, Nour Eissa, Hongxing Wang, Kunal Kapoor, Abdoulaye Diarra, Abdelilah S. Gounni, Charles N. Bernstein, Jean‐Eric Ghia in Volume 176, Issue 9, pages 1235-1250

Background and Purpose

An alteration in the communication between the innate and adaptive immune cells is a hallmark of ulcerative colitis (UC). Semaphorin‐3E (SEMA3E), a secreted guidance protein, regulates various immune responses.

Experimental Approach

We investigated the expression of SEMA3E in colonic biopsies of active UC patients and its mechanisms in Sema3e−/− mice using an experimental model of UC.

Key Results

SEMA3E level was decreased in active UC patients and negatively correlated with pro‐inflammatory mediators. Colonic expression of SEMA3E was reduced in colitic Sema3e+/+ mice, and recombinant (rec‐) Plexin‐D1 treatment exacerbated disease severity. In vivo rec‐SEMA3E treatment restored SEMA3E level in colitic Sema3e+/+ mice. In Sema3e−/− mice, disease severity was increased, and rec‐SEMA3E ameliorated these effects. Lack of Sema3e increased the expression of CD11c and CD86 markers. Colitic Sema3e−/− splenocytes and splenic CD11c+ cells produced more IL‐12/23 and IFN‐γ compared to Sema3e+/+, and rec‐SEMA3E reduced their release as much as NF‐κB inhibitors, whereas an NF‐κB activator increased their production and attenuated the effect of rec‐SEMA3E. Colitic Sema3e−/− splenic CD11c+/CD4+CD25 T‐cell co‐cultures produced higher concentrations of IFN‐γ and IL‐17 when compared to colitic Sema3e+/+ splenic cell co‐cultures, and rec‐SEMA3E decreased these effects. In vitro, anti‐IL‐12p19 and ‐12p35 antibodies and rec‐IL‐12 and ‐23 treatment confirmed the crosstalk between CD11c+ and CD4+CD25 T‐cells.

Conclusion and Implications

SEMA3E is reduced in colitis and modulates colonic inflammation by regulating the interaction between CD11c+ and CD4+CD25 T‐cells via an NF‐κB‐dependent mechanism. Thus, SEMA3E could be a potential therapeutic target for UC patients.

DOI: 10.1111/bph.14614

View this article